ZYME (Zymeworks) ROCE %: -47.44% (As of Mar. 2026)


ZYME Zymeworks Inc ZYME
66 GF Score
Price $24.30
GF Value $22.11
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is Zymeworks ROCE %?

Zymeworks ZYME +1.76% 66 ROCE % is -47.44% as of Mar. 2026. GuruFocus rates ZYME with a GF Score™ of 66/100 and a GF Value™ of $22.11 (Fairly Valued). The stock has 2 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Zymeworks's annualized ROCE % for the quarter that ended in Mar. 2026 was -47.44%.

Zymeworks  (NAS:ZYME) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Zymeworks ROCE % Related Terms

Zymeworks ROCE % Historical Data

* Premium members only.

The historical data trend for Zymeworks's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zymeworks ROCE % Chart

Zymeworks Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -56.02 29.98 -25.60 -26.63 -27.26

Zymeworks Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -24.09 -0.68 -24.34 -53.52 -47.44
ZYME
66GF Score
Zymeworks Inc ZYME
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Zymeworks ROCE % Calculation

Zymeworks's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-92.535/( ( (463.091 - 88.294) + (346.527 - 42.318) )/ 2 )
=-92.535/( (374.797+304.209)/ 2 )
=-92.535/339.503
=-27.26 %

Zymeworks's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=-177.148/( ( (346.527 - 42.318) + (478.215 - 35.649) )/ 2 )
=-177.148/( ( 304.209 + 442.566 )/ 2 )
=-177.148/373.3875
=-47.44 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -47.44% mean?
Zymeworks (ZYME) has a ROCE % of -47.44% as of Mar. 2026.
Is Zymeworks' ROCE % too high?
Zymeworks' current ROCE % is -47.44%. Overall, Zymeworks has a GF Score™ of 66/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Zymeworks' ROCE % compare to ADMA and NRIX?
Zymeworks' ROCE % of -47.44% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Zymeworks's current ROCE % is -47.44%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zymeworks stock overvalued right now?
Based on GuruFocus' analysis, Zymeworks (ZYME) is currently considered Fairly Valued. The stock's GF Value™ is $22.11, compared to a current price of $24.30 — trading 9.9% above its estimated fair value. The current ROCE % is -47.44%. Zymeworks' overall GF Score™ is 66/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Zymeworks (ZYME), the current ROCE % is -47.44% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Zymeworks (ZYME) Overvalued in 2026?

Based on GuruFocus' analysis, Zymeworks stock appears to be overvalued. The current stock price of $24.30 is trading 9.9% above its estimated GF Value™ of $22.11. GuruFocus considers Zymeworks to be Fairly Valued.

Key valuation signals for ZYME:

  • ROCE %: -47.44%
  • GF Value™: $22.11 vs. price of $24.30 (9.9% above fair value)
  • GF Score™: 66/100 with 2 warning signs

No single metric tells the full story. See the ZYME stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Zymeworks Business Description

Other Exchanges ZA8:Germany
Address 108 Patriot Drive, Suite A, Middletown, DE, USA, 19709
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
66GF Score

Get the complete analysis for ZYME

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$24.30
Price
$22.11
GF Value